Aiming for cure in HBV and HDV infection.

[1]  Thorsten Lehr,et al.  Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. , 2016, Journal of hepatology.

[2]  W. Haefeli,et al.  First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. , 2016, Journal of hepatology.

[3]  U. Haberkorn,et al.  A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  S. Fletcher,et al.  Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor , 2016, Nature.

[5]  M. Dandri,et al.  Latest developments in the treatment of hepatitis B. , 2016, Minerva gastroenterologica e dietologica.

[6]  N. Pochet,et al.  A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses , 2016, Hepatology.

[7]  M. Rizzetto.  The adventure of delta , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[8]  Qiang Deng,et al.  HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. , 2015, Journal of hepatology.

[9]  B. Cullen,et al.  Targeting hepatitis B virus cccDNA using CRISPR/Cas9. , 2015, Antiviral research.

[10]  Meghan M. Holdorf,et al.  Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation , 2015, Proceedings of the National Academy of Sciences.

[11]  Laetitia Canini,et al.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. , 2015, The Lancet. Infectious diseases.

[12]  A. Zlotnick,et al.  Core protein: A pleiotropic keystone in the HBV lifecycle. , 2015, Antiviral research.

[13]  C. Coffin,et al.  The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. , 2015, Journal of hepatology.

[14]  K. Caldecott,et al.  Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair? , 2015, PloS one.

[15]  David A. Scott,et al.  CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus , 2015, Scientific Reports.

[16]  K. Simon,et al.  Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) , 2015, Hepatology.

[17]  C. Begley,et al.  Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis , 2015, Proceedings of the National Academy of Sciences.

[18]  C. Begley,et al.  Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus , 2015, Proceedings of the National Academy of Sciences.

[19]  T. Volz,et al.  O115 : High antiviral activity of the HBV core inhibitor NVR 3-778 in the humanized uPA/SCID mouse model , 2015 .

[20]  R. Iyer,et al.  P0636 : Antiviral efficacy and induction of host immune responses with SB 9200, an oral prodrug of the dinucleotide SB 9000, in the woodchuck model of chronic hepatitis B virus (HBV) infection , 2015 .

[21]  R. Kamm,et al.  G04 : Engineered HBV-specific T cells: Disentangling antiviral from killing capacity , 2015 .

[22]  P. Angus,et al.  LP40 : SB 9200, A novel immunomodulator for patients with viral hepatitis: Phase 1 mad study in patients with hepatitis c virus (HCV) infection , 2015 .

[23]  A. Zlotnick,et al.  P0529 : Anti capsid drugs HAP12 and AT130 target HBV core protein nuclear functions , 2015 .

[24]  M. Manns,et al.  Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting Polypeptide (NTCP) , 2015, PloS one.

[25]  B. Cullen,et al.  Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. , 2015, Virology.

[26]  C. Rice,et al.  The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. , 2015, Immunity.

[27]  M. Dandri,et al.  Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[28]  H. Chan,et al.  A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  G. Gerken,et al.  Toll‐like receptor‐mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen , 2014, Journal of viral hepatitis.

[30]  C. Seeger,et al.  Targeting Hepatitis B Virus With CRISPR/Cas9 , 2014, Molecular therapy. Nucleic acids.

[31]  S. Lewin,et al.  Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B , 2014, Gut.

[32]  J. Marchand,et al.  TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice , 2014, Gut.

[33]  Roger Williams,et al.  Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production , 2014, Gastroenterology.

[34]  Q. Ning,et al.  Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). , 2014, Journal of hepatology.

[35]  M. Nassal,et al.  Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses , 2014, Proceedings of the National Academy of Sciences.

[36]  A. Gaggar,et al.  Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. , 2014, Vaccine.

[37]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[38]  M. Buti,et al.  Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians , 2014, Gut.

[39]  G. Gerken,et al.  Long‐term stimulation of Toll‐like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly I:C treatment , 2014, Journal of viral hepatitis.

[40]  Jian-Ping Zuo,et al.  Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion. , 2014, Antiviral research.

[41]  M. Manns,et al.  Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta , 2014, Hepatology.

[42]  J. Schiffer,et al.  AAV-Mediated Delivery of Zinc Finger Nucleases Targeting Hepatitis B Virus Inhibits Active Replication , 2014, PloS one.

[43]  M. Gregory,et al.  P1044 NVP018, A CYCLOPHILIN INHIBITOR FOR TREATMENT OF CHRONIC HBV INFECTION , 2014 .

[44]  M. Buti,et al.  P1089 ADD-ON THERAPY WITH ENTECAVIR PLUS TENOFOVIR DUE TO VIRAL RESISTANCE OR PARTIAL RESPONSES FOLLOWED BY MONOTHERAPY IN CHB-PATIENTS: FINAL RESULTS FROM AN INTERNATIONAL MULTICENTRE STUDY , 2014 .

[45]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[46]  A. Mai,et al.  Epigenetic drugs targeting cccDNA-bound chromatin modifying enzymes silence HBV transcription and inhibit viral replication , 2014 .

[47]  N. Obeng-Adjei,et al.  DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques , 2013, Cancer Gene Therapy.

[48]  Xiaoyan Chen,et al.  Characterization of metabolites of GLS4 in humans using ultrahigh-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. , 2013, Rapid communications in mass spectrometry : RCM.

[49]  Wenhui Li,et al.  Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes , 2013, PLoS pathogens.

[50]  A. Jilbert,et al.  Nucleic Acid Polymers Inhibit Duck Hepatitis B Virus Infection In Vitro , 2013, Antimicrobial Agents and Chemotherapy.

[51]  A. Jilbert,et al.  Nucleic Acid Polymers Prevent the Establishment of Duck Hepatitis B Virus Infection In Vivo , 2013, Antimicrobial Agents and Chemotherapy.

[52]  M. Aichler,et al.  T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. , 2013, Gastroenterology.

[53]  T. Cathomen,et al.  Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  R. Lanford,et al.  GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. , 2013, Gastroenterology.

[55]  K. Reddy,et al.  A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection , 2013, PloS one.

[56]  J. Prieto,et al.  Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis. , 2013 .

[57]  A. Lohse,et al.  The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. , 2013, Journal of hepatology.

[58]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[59]  Alan McLachlan,et al.  Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  M. Buendia,et al.  Methyltransferase PRMT1 Is a Binding Partner of HBx and a Negative Regulator of Hepatitis B Virus Transcription , 2013, Journal of Virology.

[61]  W. Rosenberg,et al.  Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection , 2012, PloS one.

[62]  Jia Liu,et al.  Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. , 2012, Journal of hepatology.

[63]  D. Vassilopoulos,et al.  Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. , 2012, Gastroenterology.

[64]  Lai Wei,et al.  In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations , 2012, Antiviral therapy.

[65]  A. Cuconati,et al.  Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation , 2012, Antimicrobial Agents and Chemotherapy.

[66]  M. Dandri,et al.  New insight in the pathobiology of hepatitis B virus infection , 2012, Gut.

[67]  M. Buti,et al.  Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. , 2012, Journal of hepatology.

[68]  A. Lohse,et al.  Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation , 2012, Hepatology.

[69]  M. Levrero,et al.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. , 2012, The Journal of clinical investigation.

[70]  J. Belghiti,et al.  Antiviral Activity of Bay 41-4109 on Hepatitis B Virus in Humanized Alb-uPA/SCID Mice , 2011, PloS one.

[71]  F. Zoulim,et al.  The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. , 2011, Antiviral research.

[72]  Fabien Zoulim,et al.  Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. , 2011, Journal of hepatology.

[73]  P. Hainaut,et al.  Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells , 2011, PloS one.

[74]  A. Bertoletti,et al.  Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.

[75]  M. Maini,et al.  Role of the coinhibitory receptor cytotoxic T lymphocyte antigen‐4 on apoptosis‐Prone CD8 T cells in persistent hepatitis B virus infection , 2011, Hepatology.

[76]  A. Zlotnick,et al.  Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. , 2010, ACS chemical biology.

[77]  J. Haas,et al.  The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus‐specific CD8+ T‐cell function , 2010, Hepatology.

[78]  M. Maini,et al.  Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection , 2010, PLoS pathogens.

[79]  A. Cuconati,et al.  Synthesis and Biological Evaluation of Triazolo-pyrimidine Derivatives as Novel Inhibitors of Hepatitis B Virus Surface Antigen (HBsAg) Secretion , 2010 .

[80]  M. Massari,et al.  Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. , 2010, Gastroenterology.

[81]  M. Levrero,et al.  Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function , 2009, Proceedings of the National Academy of Sciences.

[82]  S. Locarnini,et al.  Hepatitis: Monitoring drug therapy for hepatitis B—a global challenge? , 2009, Nature Reviews Gastroenterology &Hepatology.

[83]  M. Levrero,et al.  Control of cccDNA function in hepatitis B virus infection. , 2009, Journal of hepatology.

[84]  Rachel Wilson,et al.  Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro , 2009, Antiviral therapy.

[85]  P. Marcellin,et al.  Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2009, Hepatology.

[86]  Dongliang Yang,et al.  Hepatitis B virus suppresses toll‐like receptor–mediated innate immune responses in murine parenchymal and nonparenchymal liver cells , 2009, Hepatology.

[87]  U. Haberkorn,et al.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein , 2008, Nature Biotechnology.

[88]  A. Quaas,et al.  Sequential Combination Therapy Leads to Biochemical and Histological Improvement Despite Low Ongoing Intrahepatic Hepatitis B virus Replication , 2008, Antiviral therapy.

[89]  G. Gerken,et al.  Toll‐like receptor‐mediated control of HBV replication by nonparenchymal liver cells in mice , 2007, Hepatology.

[90]  S. Locarnini,et al.  The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. , 2007, Antiviral research.

[91]  S. Locarnini,et al.  Toll‐like receptors, RIG‐I‐like RNA helicases and the antiviral innate immune response , 2007, Immunology and cell biology.

[92]  F. Zoulim,et al.  Glucosidase inhibitors as antiviral agents for hepatitis B and C. , 2007, Current opinion in investigational drugs.

[93]  S. Lewin,et al.  Regulation of Toll‐like receptor‐2 expression in chronic hepatitis B by the precore protein , 2007, Hepatology.

[94]  P. Schirmacher,et al.  Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B , 2006, Hepatology.

[95]  M. Levrero,et al.  Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. , 2006, Gastroenterology.

[96]  M. Yuen,et al.  One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels , 2005, Antiviral therapy.

[97]  A. Zlotnick,et al.  A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[98]  V. Wong,et al.  Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. , 2005, Gastroenterology.

[99]  C. Rice,et al.  Interfering with hepatitis C virus RNA replication. , 2004, Virus research.

[100]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[101]  Ping Liu,et al.  In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. , 2003, The Journal of clinical investigation.

[102]  B. Beckermann,et al.  Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids , 2003, Science.

[103]  M. Kay,et al.  A Prenylation Inhibitor Prevents Production of Infectious Hepatitis Delta Virus Particles , 2002, Journal of Virology.

[104]  W. Delaney,et al.  Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[105]  A. Caudy,et al.  Role for a bidentate ribonuclease in the initiation step of RNA interference , 2001 .

[106]  S. Hammond,et al.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells , 2000, Nature.

[107]  R. Dwek,et al.  Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[108]  P. Schmid,et al.  Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infection , 2016 .

[109]  M. Heikenwalder,et al.  Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. , 2016, Gastroenterology.

[110]  D. Grimm,et al.  RNA Interference Mediated Suppression of HBV Transcripts Restores HBV-Specific Immunity and Enhances the Efficacy of Therapeutic Vaccination , 2016 .

[111]  R. Idilman,et al.  Hepatitis Delta Virus Kinetics under the Prenylation Inhibitor Lonafarnib Suggest HDV-Mediated Suppression of HBV Replication , 2016 .

[112]  W. Haefeli,et al.  Combination of the Hepatitis B/D Entry Inhibitor Myrcludex B and Tenofovir: Assessment of the Effect on Plasma Bile Acid Profiles and Tenofovir Pharmacokinetics , 2016 .

[113]  R. Iyer,et al.  Antiviral Efficacy and Host Immune Response Induction with SB 9200, an Oral Prodrug of the Dinucleotide SB 9000, in Combination with Entecavir in the Woodchuck Model of Chronic Hepatitis B , 2016 .

[114]  M. Yuen,et al.  NVR 3-778, a First-in-Class HBV Core Inhibitor, Alone and in Combination with Peg-Interferon (PegIFN), in Treatment-Naive HBeAg-Positive Patients: Early Reductions in HBV DNA and HBeAg , 2016 .

[115]  M. Buti,et al.  Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. , 2016, Gastroenterology.

[116]  A. Bertoletti,et al.  Immunotherapy using T Cells Redirected against HBV Results in Reduced Viral Loads and Enhanced Immune Responses in Humanized Mice , 2016 .

[117]  M. Manns,et al.  Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. , 2015, Journal of hepatology.

[118]  张静,et al.  Banana Ovate family protein MaOFP1 and MADS-box protein MuMADS1 antagonistically regulated banana fruit ripening , 2015 .

[119]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[120]  R. Schwabe,et al.  Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes , 2022 .